Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.09.17	GlobeNewswire/Novartis gibt Rücktritt von CEO Joseph Jimenez per 2018 bekannt. Ernennung von Vasant Narasimhan zum neuen CEO auf 1. Februar 2018. (Dow Jones)
04.09.17	Press Release: Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. (Dow Jones)
30.08.17	Press Release: Novartis receives first ever FDA -3- (Dow Jones)
30.08.17	Press Release: Novartis receives first ever FDA -2- (Dow Jones)
30.08.17	Press Release: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that i... (Dow Jones)
27.08.17	Press Release: Novartis announces analysis -2- (Dow Jones)
27.08.17	Press Release: Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studi... (Dow Jones)
27.08.17	Press Release: Novartis Phase III CANTOS study -2- (Dow Jones)
27.08.17	Press Release: Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk (Dow Jones)
24.08.17	Press Release: Novartis appoints Bertrand Bodson as Chief Digital Officer (Dow Jones)
24.08.17	Press Release: Novartis Kisqali(R) (ribociclib) -2- (Dow Jones)
24.08.17	Press Release: Novartis Kisqali(R) (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in co... (Dow Jones)
21.08.17	Press Release: Novartis and Medicines for Malaria -2- (Dow Jones)
21.08.17	Press Release: Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria (Dow Jones)
21.08.17	GlobeNewswire/Novartis et Medicines for Malaria -2- (Dow Jones)
21.08.17	GlobeNewswire/Novartis et Medicines for Malaria Venture lancent une étude clinique en Afrique pour KAF156, un candidat-médicament novateur contre le palud... (Dow Jones)
25.07.17	Press Release: Novartis: Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries (Dow Jones)
21.07.17	Press Release: Novartis receives positive CHMP -3- (Dow Jones)
21.07.17	Press Release: Novartis receives positive CHMP -2- (Dow Jones)
21.07.17	Press Release: Novartis receives positive CHMP opinion for Rydapt(R) (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three ty... (Dow Jones)
18.07.17	Press Release: Q2 results confirm full year -5- (Dow Jones)
18.07.17	Press Release: Q2 results confirm full year -4- (Dow Jones)
18.07.17	Press Release: Q2 results confirm full year -3- (Dow Jones)
18.07.17	Press Release: Q2 results confirm full year -2- (Dow Jones)
18.07.17	Press Release: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products (Dow Jones)
14.07.17	Press Release: Novartis confirms 5 year data for -2- (Dow Jones)
14.07.17	Press Release: Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx(R) reinforcing sustained efficacy and safety profile in... (Dow Jones)
12.07.17	Press Release: Novartis CAR-T cell therapy CTL019 -2- (Dow Jones)
12.07.17	Press Release: Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B... (Dow Jones)
06.07.17	Press Release: Novartis receives approval in the -2- (Dow Jones)
06.07.17	Press Release: Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis (Dow Jones)
29.06.17	Press Release: Novartis receives EU approval for -2- (Dow Jones)
29.06.17	Press Release: Novartis receives EU approval for first-line use of Zykadia(R) in ALK-positive advanced non-small cell lung cancer (NSCLC) (Dow Jones)
23.06.17	Press Release: NEJM publishes full analysis of -2- (Dow Jones)
23.06.17	Press Release: NEJM publishes full analysis of Rydapt(R) (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) (Dow Jones)
23.06.17	Press Release: Novartis Kisqali(R) (ribociclib) -2- (Dow Jones)
23.06.17	Press Release: Novartis Kisqali(R) (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast ca... (Dow Jones)
23.06.17	Press Release: Novartis data shows half of -3- (Dow Jones)
23.06.17	Press Release: Novartis data shows half of -2- (Dow Jones)
23.06.17	Press Release: Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna(R) (Dow Jones)
23.06.17	Press Release: Novartis pivotal CTL019 6-month -2- (Dow Jones)
23.06.17	Press Release: Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL (Dow Jones)
23.06.17	Press Release: Novartis combination targeted -2- (Dow Jones)
23.06.17	Press Release: Novartis combination targeted therapy Tafinlar(R) + Mekinist(R) receives FDA approval for BRAF V600E mutant metastatic non-small cell lung can... (Dow Jones)
22.06.17	Press Release: Novartis Phase III study shows -2- (Dow Jones)
22.06.17	Press Release: Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack (Dow Jones)
21.06.17	Press Release: Novartis achieves important -2- (Dow Jones)
21.06.17	Press Release: Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance (Dow Jones)
20.06.17	Press Release: Novartis RTH258 (brolucizumab) -2- (Dow Jones)
20.06.17	Press Release: Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert